Pfizer has agreed to pay $14.5 million to settle False Claims Act allegations related to the marketing of its drug Detrol, according to a news release from the Department of Justice.
This settlement resolves the last of a group of 10 whistleblower suits filed since 2003. The other nine suits were settled or dismissed in 2009 when Pfizer agreed to pay $2.3 billion to resolve civil claims and criminal charges regarding multiple drugs.
This specific settlement resolves allegations that Pfizer illegally marketed Detrol, a drug for the treatment of overactive bladder. Of the $14.5 million recovery, $11.9 million will go to the federal government and $2.6 million to state Medicaid programs. Under the qui tam provisions of the False Claims Act, whistleblowers will receive a $3.3 million share of the federal recovery.
Related Articles on Pharmaceutical Companies and Settlements:
Wisconsin’s Ongoing Lawsuit Against Drugmakers Reaches Nearly $13M in Settlements
Harvard Drug Group Pays $8M to Settle Claims of Failure to Report Suspicious Drug Orders
Teva Loses $144M Damages Claim to Baxter, Must Compensate Infected Patient $500M
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
